Eli Lilly and Company (NYSE:LLY) Shares Up 0.4% – Still a Buy?

Eli Lilly and Company (NYSE:LLY)’s stock price rose 0.4% during trading on Monday . The company traded as high as $805.35 and last traded at $798.65. Approximately 965,597 shares traded hands during trading, a decline of 70% from the average daily volume of 3,202,716 shares. The stock had previously closed at $795.35.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of recent research reports. Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Truist Financial boosted their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research note on Thursday, October 10th. Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Bank of America decreased their target price on shares of Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating for the company in a research note on Thursday, October 31st. Finally, BMO Capital Markets lifted their price target on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $1,007.94.

Eli Lilly and Company Trading Up 0.3 %

The stock has a market cap of $756.95 billion, a price-to-earnings ratio of 86.34, a price-to-earnings-growth ratio of 3.01 and a beta of 0.43. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The firm’s 50 day moving average is $851.90 and its two-hundred day moving average is $870.85.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. During the same quarter in the previous year, the business posted $0.10 earnings per share. The business’s quarterly revenue was up 20.4% compared to the same quarter last year. Equities analysts anticipate that Eli Lilly and Company will post 13.2 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.65%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio is currently 56.22%.

Insider Activity at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.13% of the stock is currently owned by insiders.

Institutional Trading of Eli Lilly and Company

A number of large investors have recently added to or reduced their stakes in the business. American Trust lifted its stake in Eli Lilly and Company by 4.6% during the third quarter. American Trust now owns 2,603 shares of the company’s stock valued at $2,306,000 after buying an additional 115 shares in the last quarter. Tidal Investments LLC lifted its position in shares of Eli Lilly and Company by 20.5% in the 3rd quarter. Tidal Investments LLC now owns 49,562 shares of the company’s stock valued at $43,909,000 after acquiring an additional 8,424 shares in the last quarter. Optimist Retirement Group LLC grew its position in Eli Lilly and Company by 20.2% during the 3rd quarter. Optimist Retirement Group LLC now owns 3,164 shares of the company’s stock worth $2,803,000 after purchasing an additional 531 shares in the last quarter. Blankinship & Foster LLC acquired a new stake in Eli Lilly and Company during the 3rd quarter valued at $78,003,000. Finally, Destination Wealth Management lifted its holdings in shares of Eli Lilly and Company by 1,373.9% in the third quarter. Destination Wealth Management now owns 27,326 shares of the company’s stock valued at $24,209,000 after purchasing an additional 25,472 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.